Patents by Inventor Gregory D. Vite

Gregory D. Vite has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrrolotriazine compounds as kinase inhibitors
    Patent number: 7297695
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: June 26, 2006
    Date of Patent: November 20, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Ashvinikumar V. Gavai, Gregory D. Vite, Ping Chen, Harold Mastalerz, Derek J. Norris, John S. Tokarski, Yufen Zhao, Wen-Ching Han
  • Epothilone derivatives
    Patent number: 7241755
    Abstract: The present invention relates to compounds of the formula in which the variables G, W, Q, X, Y, B1, B2, Z1, Z2, and R1–R7 are as defined herein, methods for the preparation of the derivatives and intermediates thereof.
    Type: Grant
    Filed: August 30, 2006
    Date of Patent: July 10, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gregory D. Vite, Soong-Hoon Kim, Robert M. Borzilleri, James A. Johnson
  • C12-cyano epothilone derivatives
    Patent number: 7211593
    Abstract: The present invention relates to compounds useful in the treatment of cancer or other proliferative diseases represented by the formula wherein: R1, R2, R3, R4, R5 are hydrogen or lower alkyl; R6 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, or heterocyclo; X is hydrogen and Y is hydroxy, or X and Y taken together represent a carbon-carbon bond; and pharmaceutically acceptable salts, solvates, or hydrates thereof. Also included are therapeutic compositions containing the compounds represented by formula I as active ingredients, alone or in combination with other therapeutic agents useful in the treatment of cancer or other proliferative diseases.
    Type: Grant
    Filed: March 11, 2003
    Date of Patent: May 1, 2007
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Gregory D. Vite, Alicia Regueiro-Ren
  • C-6 modified indazolylpyrrolotriazines
    Patent number: 7148220
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: December 12, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gregory D. Vite, Ashvinikumar V. Gavai, Brian E. Fink, Harold Mastalerz, John F. Kadow
  • Pyrrolotriazine compounds as kinase inhibitors
    Patent number: 7141571
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: November 28, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Ashvinikumar V. Gavai, Gregory D. Vite, Ping Chen, Harold Mastalerz, Derek J. Norris, John S. Tokarski, Yufen Zhao, Wen-Ching Han
  • Epothilone derivatives
    Patent number: 7125899
    Abstract: The present invention relates to epothilone derivatives, having the following formula: in which the variables G, W, Q, X, Y, B1, B2, Z1, Z2, and R1–R7 are defined herein, methods for preparation of the derivatives and intermediates thereof.
    Type: Grant
    Filed: April 3, 2003
    Date of Patent: October 24, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gregory D. Vite, Soong-Hoon Kim, Robert M. Borzilleri, James A. Johnson
  • C-6 modified indazolylpyrrolotriazines
    Patent number: 6916815
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: December 15, 2003
    Date of Patent: July 12, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gregory D. Vite, Ashvinikumar V. Gavai, Brian E. Fink, Harold Mastalerz, John F. Kadow
  • C-5 modified indazolylpyrrolotriazines
    Patent number: 6908916
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: November 14, 2002
    Date of Patent: June 21, 2005
    Assignee: Bristol Myers Squibb Company
    Inventors: Harold Mastalerz, Guifen Zhang, James G. Tarrant, Gregory D. Vite
  • 2,3-olefinic epothilone derivatives
    Patent number: 6831090
    Abstract: The present invention relates to 2,3-position modified epothilone derivatives, methods of preparation of the derivatives, and intermediates therefor. The compounds of the invention as 16-membered macrolides having the general structure, which have microtubule-stabilizing effects and cytotoxic activity against rapidly proliferating cells, such as, tumor cells or other hyperproliferative cellular disease.
    Type: Grant
    Filed: September 13, 2002
    Date of Patent: December 14, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gregory D. Vite, Robert M. Borzilleri, Gerhard Höfle, Thomas Leibold
  • Epothilone derivatives
    Patent number: 6800653
    Abstract: The present invention relates to 12,13-position modified epothilone derivatives, methods of preparation of the derivatives, and intermediates therefor.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: October 5, 2004
    Assignee: Bristol-Myers Squibb Compnay
    Inventors: Alicia Regueiro-Ren, Robert M. Borzilleri, Gregory D. Vite, Soong-Hoon Kim
  • C-6 modified indazolylpyrrolotriazines
    Publication number: 20040142931
    Abstract: The present invention provides compounds of formula I 1
    Type: Application
    Filed: December 15, 2003
    Publication date: July 22, 2004
    Inventors: Gregory D. Vite, Ashvinikumar V. Gavai, Brian E. Fink, Harold Mastalerz, John F. Kadow
  • Preparation of epothilone intermediates
    Publication number: 20040023345
    Abstract: The present invention relates to a process for the preparation of intermediates useful in the synthesis of epothilone analogs by initially enzymatically degrading certain epothilone compounds to form ring-open structures containing a carboxyl group which is esterified, the hydroxyl groups on the moiety protected and the resulting compound oxidized by, e.g. ozone, to form a first intermediate. The first intermediate can be reacted with a triphenylphosphine adduct to yield a compound containing an ester group at position 1 which is subsequently hydrolyzed to form a second intermediate.
    Type: Application
    Filed: May 28, 2003
    Publication date: February 5, 2004
    Inventors: Gregory D. Vite, Soong-Hoon Kim, Gerhard Hofle
  • Epothilone derivatives
    Publication number: 20030220295
    Abstract: The present invention relates to compounds of the formula 1
    Type: Application
    Filed: April 3, 2003
    Publication date: November 27, 2003
    Inventors: Gregory D. Vite, Soong-Hoon Kim, Robert M. Borzilleri, James A. Johnson
  • C12-cyano epothilone derivatives
    Publication number: 20030186965
    Abstract: The present invention relates to compounds useful in the treatment of cancer or other proliferative diseases represented by the formula 1
    Type: Application
    Filed: March 11, 2003
    Publication date: October 2, 2003
    Inventors: Gregory D. Vite, Alicia Regueiro-Ren
  • C-5 Modified indazolylpyrrolotriazines
    Publication number: 20030186983
    Abstract: The present invention provides compounds of formula I 1
    Type: Application
    Filed: November 14, 2002
    Publication date: October 2, 2003
    Inventors: Harold Mastalerz, Guifen Zhang, James G. Tarrant, Gregory D. Vite
  • Epothilone derivatives
    Patent number: 6605599
    Abstract: The present invention relates to epothilone derivatives, having the following formula in which the variables G, W, Q, X, Y, B1, B2, Z1, Z2, and R1-R7 are as defined herein, methods for the preparation of the derivatives and intermediates thereof.
    Type: Grant
    Filed: May 26, 1998
    Date of Patent: August 12, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gregory D. Vite, Soong-Hoon Kim, Robert M. Borzilleri, James A. Johnson
  • Preparation of epothilone intermediates
    Patent number: 6593115
    Abstract: The present invention relates to a process for the preparation of intermediates useful in the synthesis of epothilone analogs by initially enzymatically degrading certain epothilone compounds to form ring-open structures containing a carboxyl group which is esterified, the hydroxyl groups on the moiety protected and the resulting compound oxidized by, e.g. ozone, to form a first intermediate. The first intermediate can be reacted with a triphenylphosphine adduct to yield a compound containing an ester group at position 1 which is subsequently hydrolyzed to form a second intermediate.
    Type: Grant
    Filed: March 19, 2001
    Date of Patent: July 15, 2003
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Gregory D. Vite, Soong-Hoon Kim, Gerhard Höfle
  • Epothilone derivatives
    Publication number: 20030087888
    Abstract: The present invention relates to 12,13-position modified epothilone derivatives, methods of preparation of the derivatives, and intermediates therefor.
    Type: Application
    Filed: May 14, 2002
    Publication date: May 8, 2003
    Inventors: Alicia Regueiro-Ren, Robert M. Borzilleri, Gregory D. Vite, Soong-Hoon Kim
  • 2,3-Olefinic epothilone derivatives
    Publication number: 20030060623
    Abstract: The present invention relates to 2,3-position modified epothilone derivatives, methods of preparation of the derivatives, and intermediates therefor.
    Type: Application
    Filed: September 13, 2002
    Publication date: March 27, 2003
    Applicant: Bristol-Myers Squibb Co.
    Inventors: Gregory D. Vite, Robert M. Borzilleri, Gerhard Hofle, Thomas Leibold
  • 2,3-olefinic epothilone derivatives
    Patent number: 6498257
    Abstract: The present invention relates to 2,3-position modified epothilone derivatives, methods of preparation of the derivatives, and intermediates therefor. The compounds of the invention as 16-membered macrolides having the general structure, which have microtubule-stabilizing effects and cytotoxic activity against rapidly proliferating cells, such as, tumor cells or other hyperproliferative cellular disease.
    Type: Grant
    Filed: March 29, 1999
    Date of Patent: December 24, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gregory D. Vite, Robert M. Borzilleri, Gerhard Höfle, Thomas Leibold